Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing lung disease that leads to unrelenting dyspnoea and chronic cough, and ultimately respiratory failure [1]. IPF is characterised by a variable disease course that remains difficult to predict for an individual at diagnosis [2]. In the current era, with the advent of anti-fibrotic therapy which can slow disease progression, it is increasingly important to identify patients with early disease and to target those patients who are at most risk of rapid decline [3]. However, despite multiple studies proposing novel potential prognostic biomarkers, the current American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society guideline statements dismissed the use of these biomarkers except in a research capacity [3, 4]. Blood monocytes have been recently proposed as a potential prognostic marker for IPF. Data from the Australian IPF registry have shown that elevated monocytes, neutrophils and total leukocytes significantly predict poorer survival in IPF patients. http://bit.ly/38GP7f0

中文翻译：

---

血液单核细胞计数作为 IPF 的潜在预后标志物：来自澳大利亚 IPF 登记处的分析

特发性肺纤维化 (IPF) 是一种慢性、进行性、纤维化的肺部疾病，可导致持续的呼吸困难和慢性咳嗽，并最终导致呼吸衰竭 [1]。IPF 的特点是病程多变，在诊断时仍然难以预测个体 [2]。在当前时代，随着可以减缓疾病进展的抗纤维化治疗的出现，识别早期疾病患者并针对那些最有可能快速衰退的患者变得越来越重要[3]。然而，尽管多项研究提出了新的潜在预后生物标志物，但当前的美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会指南声明驳回了这些生物标志物的使用，除非是出于研究目的 [3, 4]。最近有人提出血液单核细胞作为 IPF 的潜在预后标志物。来自澳大利亚 IPF 登记处的数据表明，升高的单核细胞、中性粒细胞和总白细胞显着预测 IPF 患者较差的存活率。http://bit.ly/38GP7f0